Kalytera Therapeutics, Inc., a pharmaceutical company developing a portfolio of proprietary cannabinoid and endocannabinoid-like medicines, has announced the appointment of Dr. Stuart Silverman, M.D., FACP, FACR, as Senior Vice President of Medical Affairs. Dr. Silverman will also serve on Kalytera’s Board of Directors and as Co-Chair of Kalytera’s Scientific Advisory Board.
“I am honored to fill this important position,” said Dr. Silverman. “I will initially support the advancement of our development programs in osteoporosis, bone fracture healing, and osteogenesis imperfecta. Preclinical data supports the continued investigation of Kalytera’s drug candidates in these areas. In addition, recent mainstream media coverage has highlighted patient concerns about starting or continuing existing osteoporosis medications due to perceived side effects. As a clinician, I recognize that there is a significant need for effective new therapies with favorable side effect profiles.”
Dr. Silverman is a Clinical Professor of Medicine at the University of California, Los Angeles, David Geffen School of Medicine. He is a member of the International Osteoporosis Foundation’s (“IOF”) Committee of Scientific Advisors. In addition, he is the American Society of Bone and Mineral Research representative to the National Osteoporosis Foundation Interspecialty Medical Council.
Dr. Silverman developed the Osteoporosis Assessment Questionnaire, or OPAQ, a measure of quality of life in osteoporosis used globally, and was part of the World Health Organization task force that developed FRAX, an international algorithm to assess ten-year fracture risk. He recently led an IOF consensus report on fracture healing.
“Dr. Silverman is a highly respected and influential authority on osteoporosis and bone health and we’re thrilled to have him as a member of our leadership team,” said Dr. Raphael Mechoulam, Ph.D., Co-Chair of Kalytera’s Scientific Advisory Board. “Stuart’s deep knowledge of bone, and his experience as a medical practitioner, will be of great value to Kalytera as we advance towards human clinical studies.”